Brokerages expect ICU Medical, Inc. (NASDAQ:ICUI) to report $321.44 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for ICU Medical’s earnings. The highest sales estimate is $329.48 million and the lowest is $313.40 million. ICU Medical reported sales of $96.72 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 232.3%. The company is expected to issue its next earnings results after the market closes on Wednesday, August 9th.
On average, analysts expect that ICU Medical will report full year sales of $321.44 million for the current year, with estimates ranging from $1.23 billion to $1.25 billion. For the next fiscal year, analysts expect that the firm will post sales of $1.33 billion per share, with estimates ranging from $1.32 billion to $1.34 billion. Zacks’ sales averages are a mean average based on a survey of research analysts that cover ICU Medical.
ICU Medical (NASDAQ:ICUI) last released its quarterly earnings results on Wednesday, May 10th. The medical instruments supplier reported $1.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.45 by $1.23. The business had revenue of $247.74 million during the quarter, compared to the consensus estimate of $237.12 million. ICU Medical had a return on equity of 9.63% and a net margin of 18.76%. The company’s quarterly revenue was up 175.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.26 EPS.
ICUI has been the subject of a number of analyst reports. Roth Capital downgraded shares of ICU Medical from a “buy” rating to a “neutral” rating in a research note on Thursday, May 11th. They noted that the move was a valuation call. BidaskClub raised shares of ICU Medical from a “hold” rating to a “buy” rating in a research report on Saturday, June 17th. Zacks Investment Research downgraded shares of ICU Medical from a “hold” rating to a “strong sell” rating in a research report on Wednesday, May 3rd. Finally, Sidoti downgraded shares of ICU Medical from a “buy” rating to a “neutral” rating in a research report on Tuesday, June 20th. Five research analysts have rated the stock with a hold rating, The stock presently has an average rating of “Hold” and a consensus target price of $157.00.
In other news, Director Joseph R. Saucedo sold 4,500 shares of ICU Medical stock in a transaction on Tuesday, May 16th. The shares were sold at an average price of $162.51, for a total transaction of $731,295.00. Following the transaction, the director now owns 3,091 shares in the company, valued at approximately $502,318.41. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Robert S. Swinney sold 594 shares of ICU Medical stock in a transaction on Wednesday, May 17th. The stock was sold at an average price of $160.92, for a total transaction of $95,586.48. Following the transaction, the director now owns 14,793 shares in the company, valued at approximately $2,380,489.56. The disclosure for this sale can be found here. Insiders have sold a total of 222,872 shares of company stock worth $37,839,895 in the last quarter. Corporate insiders own 15.90% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. boosted its position in ICU Medical by 87,088.7% in the first quarter. BlackRock Inc. now owns 1,769,930 shares of the medical instruments supplier’s stock worth $270,268,000 after buying an additional 1,767,900 shares during the period. Janus Capital Management LLC increased its stake in shares of ICU Medical by 178.8% in the first quarter. Janus Capital Management LLC now owns 1,439,864 shares of the medical instruments supplier’s stock worth $219,864,000 after buying an additional 923,395 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of ICU Medical by 12.1% in the first quarter. Wellington Management Group LLP now owns 652,897 shares of the medical instruments supplier’s stock worth $99,697,000 after buying an additional 70,283 shares in the last quarter. Champlain Investment Partners LLC increased its stake in shares of ICU Medical by 4.6% in the first quarter. Champlain Investment Partners LLC now owns 496,220 shares of the medical instruments supplier’s stock worth $75,773,000 after buying an additional 21,630 shares in the last quarter. Finally, GW&K Investment Management LLC increased its stake in shares of ICU Medical by 2.7% in the second quarter. GW&K Investment Management LLC now owns 495,697 shares of the medical instruments supplier’s stock worth $85,508,000 after buying an additional 12,808 shares in the last quarter. Institutional investors own 77.90% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “ICU Medical, Inc. (NASDAQ:ICUI) Expected to Post Quarterly Sales of $321.44 Million” was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://stocknewstimes.com/2017/07/18/icu-medical-inc-nasdaqicui-expected-to-post-quarterly-sales-of-321-44-million.html.
ICU Medical (ICUI) traded down 0.35% during trading on Friday, reaching $172.65. The company’s stock had a trading volume of 129,227 shares. The company has a 50-day moving average of $166.30 and a 200 day moving average of $152.58. ICU Medical has a one year low of $108.51 and a one year high of $176.50. The firm has a market cap of $3.42 billion, a PE ratio of 30.69 and a beta of 0.37.
ICU Medical Company Profile
ICU Medical, Inc is engaged in the development, manufacture and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, custom infusion sets, closed system transfer devices (CSTD) for the handling of hazardous drugs, advanced sensor catheters, needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems.
Get a free copy of the Zacks research report on ICU Medical (ICUI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ICU Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
